Hemodialysis ComplicationClotVarNCT06140563
Variability in Micro-CT Imaging Results to Quantify Dialyzer Clotting
A study testing anticoagulation dosing in people with Hemodialysis Complication and Anticoagulants, run by University Hospital, Ghent at 1 site in Belgium.
Trial summary
Different cross-over studies have been performed investigating dialyzer fiber patency in different dialysis setups. Herewith, post dialysis micro computed tomography (CT) images of the dialyzer were compared. For the best interpretation of such results, one should have an idea about the intrapatient variability. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hemodialysis Complication, Anticoagulants
- What is being tested?
- anticoagulation dosing
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteBelgium
- Study dates
- 8 Jan 2024to 15 Feb 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- stable chronic hemodialysis patient
- well functioning vascular access
Who cannot join
- ultrafiltration rate higher than 4 litre per session
- use of antiplatelets or anticoagulants (apart from acetylsalicylic acid)
- known coagulation disorder
- active inflammation
- malignancy
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Prospective Study of Micro-CT Imaging to Quantify Dialyzer Clotting in Patients With End Stage Kidney Disease Undergoing Hemodialysis
Different cross-over studies have been performed investigating dialyzer fiber patency in different dialysis setups. Herewith, post dialysis micro computed tomography (CT) images of the dialyzer were compared. For the best interpretation of such results, one should have an idea about the intrapatient variability. There is also no clue about the impact of long distance transportation and long cold storage on the reproducibility of the micro CT images. Another bottle neck is that, up till now, no biochemical parameter or test has been found associated with the outcome of dialyzer fiber patency post dialysis.
The present study therefore aims at determining the intrapatient variability and the impact on the micro CT results of long distance transportation and long cold storage of the dialyzers. Also, whole blood thrombin generation tests are performed to look for associations with the micro CT results.
Read the detailed description
During recent years, different coagulation studies were performed using micro computed tomography (CT) scanning of hemodialyzers post dialysis as a marker for fiber blocking. Each of these studies investigated the impact of either anticoagulation strategy, dialysis strategy, or hemodialyzer type in a cross-over study design in which each patient served as his/her own control.
To date, we still need to answer some remaining questions related to studies using micro CT before we can expand the research and clinical applications to a larger scale:
First, the power of such cross-over studies, with a single session per study arm, depends also partially on the variability over time in the micro CT results within a single patient. While the resolution (25µm) and reproducibility of the micro CT process is established, patients' coagulation status will cause the largest variability in dialyzer outcome among consecutive dialysis sessions, e.g. variation due to infection or vascular access problems. This type of intrapatient variability, quantifying dialyzer outcome with micro CT from comparable but different dialysis sessions, has not yet been studied. Evaluation of the inter- and intra-patient variability of micro CT of dialyzers in chronic hemodialysis patients will inform whether this novel method can be used as an endpoint in future interventional trials of novel anticoagulants.
Second, the micro CT imaging technique, recently paraphrased as the gold standard to quantify clotting, is a very valuable technique in research settings. Clinical practice would profit more from a less burdensome marker of hemodialyzer performance as measured during the dialysis session (not only at the end of a dialysis session). However, none of the available online dialysis machine parameters (i.e., transmembrane pressure, arterial and venous pressure, online clearance monitoring), nor visual scoring of the dialyzer or venous chamber, nor assessment of dialyzer mass post-treatment correlated well with the results of micro CT. Also, the commonly used biochemical parameters only focus on one aspect in the coagulation cascade or/and are not sensitive enough to measure variations in the coagulation system of the patient. As a consequence, they are poorly related to dialyzer outcome as quantified with micro CT. While thrombin generation (TG) is commonly determined in plasma to identify global coagulation phenotype, whole blood TG (WB-TG) tests better mimic physiology by involving also the intrinsic blood cells and platelets, making it a potential biomarker test for coagulation, and this requires investigation.
Third, the previously described studies were all executed at the Ghent University Hospital where dialyzers are prepared for scanning on the spot (i.e., rinsed, dried and stored at 5°C), and with only a short transport time (15min) from the clinic to the micro CT scanner. No hard evidence however exists whether dialyzers, after being prepared for micro CT in a different place, might be transported by flight in e.g. isolated boxes (lasting hours to days). This study will be conducted in collaboration with Regeneron (New York) where a subset of 10 dialyzers will be shipped, imaged using Regeneron's micro CT scanner, and shipped back to Ghent University for repeat imaging.
The main aims of the proposed study are therefore:
- to determine intrapatient variability of dialyzer fiber blocking as measured by micro CT scanning
- to investigate whether longer transportation of dialyzers might impact reproducibility of micro CT results by comparing micro CT results between long and short transportation times of dialyzers
- to determine the anticoagulant effect size of low molecular weight heparin by evaluating the difference in dialyzer fiber patency between full dose and low dose (1/4 dose) low molecular weight heparin treatment, which will inform sample size determination for future interventional studies of other anticoagulants
- Conditions
- Hemodialysis Complication, Anticoagulants
- Being tested
- anticoagulation dosing
- Keywords
- dialyzer fiber clotting
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
anticoagulation dosingOther
In one arm the normal amount of anticoagulation is administered at the dialysis start, while this is only a quarter of the normal amount of anticoagulation in the other arm.
| Study group | Role | What they receive |
|---|---|---|
| Normal anticoagulation dosing | Experimental | Patients are dialyzed during three consecutive hemodialysis sessions with an FX800 Cordiax dialyzer, blood flow of 300mL/min, dialysate flow of 500mL/min and ultrafiltration according to the needs of the patient. At the start of the dialysis session, the normal amount of anticoagulation is administered. Receives: Other: anticoagulation dosing |
| Reduced anticoagulation dosing | Experimental | Patients are dialyzed during three consecutive hemodialysis sessions with an FX800 Cordiax dialyzer, blood flow of 300mL/min, dialysate flow of 500mL/min and ultrafiltration according to the needs of the patient. At the start of the dialysis session, only one quarter of the normal amount of anticoagulation is administered. Receives: Other: anticoagulation dosing |
What is being measured
The primary outcome is the main question the study is designed to answer.
Intrapatient variability of dialyzer fiber patency
The intrapatient variability of the dialyzer fiber patency (i.e. percentage open fibers post dialysis) and the intraclass correlation coefficient (ICC) of fiber patency are calculated from the results of the post dialysis micro CT images of the dialyzer, as scanned after three consecutive dialysis sessions with the same anticoagulation dosing: one week with full anticoagulation and one week with reduced (1/4) anticoagulation.
Outcome = intrapatient variability of the percentage open fibers. Tool = micro CT scanning and computer-based determination of fiber patency.
Measured: 2 months
Secondary outcomes (3)
Impact of dialyzer storage and transport on micro CT images of dialyzer fibers
After initial scanning of the 60 dialyzers, 10 of these dialyzers will be transported to Regeneron (New York), where they will be scanned with a local micro CT scanner. After sending them back to Ghent University Hospital, dialyzers will be re-scanned. In the meantime, 10 other dialyzers (out of the 60 dialyzers) will be stored, after initial scanning, in a fridge in Ghent University Hospital. They will be re-scanned together with the ten dialyzers coming back from Regeneron.
From all these micro CT images, fiber patency will be derived and comparisons are made between the results before versus after transport, and before versus after longer storage in the fridge.
Outcome = comparisons between the percentage open fibers in the same filter either being transported or stored.
Tool = micro CT scanning and computer-based determination of fiber patency.
Measured: 3 months
Association between whole blood thrombin generation test and fiber patency
During each dialysis session, blood is sampled at the dialysis start and end to perform a whole blood thrombin generation test. Post dialysis, dialyzers are scanned with a micro CT scanner and the corresponding fiber patency is derived.
Outcome = Associations between parameters of the whole blood thrombin generation test and the dialyzer fiber patency.
Tools = Whole blood thrombin generation tests on blood samples and micro CT scanning and computer-based determination of fiber patency.
Measured: 2 months
Difference in fiber patency using normal versus reduced anticoagulation dosing.
Patients are followed three dialysis sessions per week, one week with full anticoagulation dosing and one week with reduced (1/4) anticoagulation dosing. Post dialysis, dialyzers are scanned with a micro CT scanner and the corresponding fiber patency is derived.
Outcome = Comparisons between the percentage open fibers in dialyzers after a session with full anticoagulation versus after a session with reduced anticoagulation.
Tool = micro CT scanning and computer-based determination of fiber patency.
Measured: 2 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Nov 2023
- Study start8 Jan 2024
- Primary completion31 Jan 2024
- Study completion15 Feb 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hemodialysis ComplicationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Ghent
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Wim Van Biesen, PhD, Principal investigator, University Hospital, Ghent
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06140563
- Sponsor's protocol ID
- ONZ-2023-0201
- Acronym
- ClotVar
- Status last verified
- Feb 2024
- First submitted
- 13 Nov 2023
- Last updated
- 22 Feb 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Study of Micro-CT Imaging to Quantify Dialyzer Clotting in Patients With End Stage Kidney Disease Undergoing Hemodialysis
- ClinicalTrials.gov ID
- NCT06140563
- Acronym / sponsor ID
- ClotVar / ONZ-2023-0201
- Conditions
- Hemodialysis Complication, Anticoagulants
- Keywords
- dialyzer fiber clotting
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 10 participants (actual)
- Lead sponsor
- University Hospital, GhentUniversity, hospital or other
- Study start
- 8 Jan 2024 (actual)
- Primary completion
- 31 Jan 2024 (actual)
- Study completion
- 15 Feb 2024 (actual)
- First posted
- 20 Nov 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Different cross-over studies have been performed investigating dialyzer fiber patency in different dialysis setups. Herewith, post dialysis micro computed tomography (CT) images of the dialyzer were compared. For the best interpretation of such results, one should have an idea about the intrapatient variability. There is also no clue about the impact of long distance transportation and long cold storage on the reproducibility of the micro CT images. Another bottle neck is that, up till now, no biochemical parameter or test has been found associated with the outcome of dialyzer fiber patency post dialysis.
The present study therefore aims at determining the intrapatient variability and the impact on the micro CT results of long distance transportation and long cold storage of the dialyzers. Also, whole blood thrombin generation tests are performed to look for associations with the micro CT results.
Detailed description
During recent years, different coagulation studies were performed using micro computed tomography (CT) scanning of hemodialyzers post dialysis as a marker for fiber blocking. Each of these studies investigated the impact of either anticoagulation strategy, dialysis strategy, or hemodialyzer type in a cross-over study design in which each patient served as his/her own control.
To date, we still need to answer some remaining questions related to studies using micro CT before we can expand the research and clinical applications to a larger scale:
First, the power of such cross-over studies, with a single session per study arm, depends also partially on the variability over time in the micro CT results within a single patient. While the resolution (25µm) and reproducibility of the micro CT process is established, patients' coagulation status will cause the largest variability in dialyzer outcome among consecutive dialysis sessions, e.g. variation due to infection or vascular access problems. This type of intrapatient variability, quantifying dialyzer outcome with micro CT from comparable but different dialysis sessions, has not yet been studied. Evaluation of the inter- and intra-patient variability of micro CT of dialyzers in chronic hemodialysis patients will inform whether this novel method can be used as an endpoint in future interventional trials of novel anticoagulants.
Second, the micro CT imaging technique, recently paraphrased as the gold standard to quantify clotting, is a very valuable technique in research settings. Clinical practice would profit more from a less burdensome marker of hemodialyzer performance as measured during the dialysis session (not only at the end of a dialysis session). However, none of the available online dialysis machine parameters (i.e., transmembrane pressure, arterial and venous pressure, online clearance monitoring), nor visual scoring of the dialyzer or venous chamber, nor assessment of dialyzer mass post-treatment correlated well with the results of micro CT. Also, the commonly used biochemical parameters only focus on one aspect in the coagulation cascade or/and are not sensitive enough to measure variations in the coagulation system of the patient. As a consequence, they are poorly related to dialyzer outcome as quantified with micro CT. While thrombin generation (TG) is commonly determined in plasma to identify global coagulation phenotype, whole blood TG (WB-TG) tests better mimic physiology by involving also the intrinsic blood cells and platelets, making it a potential biomarker test for coagulation, and this requires investigation.
Third, the previously described studies were all executed at the Ghent University Hospital where dialyzers are prepared for scanning on the spot (i.e., rinsed, dried and stored at 5°C), and with only a short transport time (15min) from the clinic to the micro CT scanner. No hard evidence however exists whether dialyzers, after being prepared for micro CT in a different place, might be transported by flight in e.g. isolated boxes (lasting hours to days). This study will be conducted in collaboration with Regeneron (New York) where a subset of 10 dialyzers will be shipped, imaged using Regeneron's micro CT scanner, and shipped back to Ghent University for repeat imaging.
The main aims of the proposed study are therefore:
- to determine intrapatient variability of dialyzer fiber blocking as measured by micro CT scanning
- to investigate whether longer transportation of dialyzers might impact reproducibility of micro CT results by comparing micro CT results between long and short transportation times of dialyzers
- to determine the anticoagulant effect size of low molecular weight heparin by evaluating the difference in dialyzer fiber patency between full dose and low dose (1/4 dose) low molecular weight heparin treatment, which will inform sample size determination for future interventional studies of other anticoagulants
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Normal anticoagulation dosing | Experimental | Other: anticoagulation dosingPatients are dialyzed during three consecutive hemodialysis sessions with an FX800 Cordiax dialyzer, blood flow of 300mL/min, dialysate flow of 500mL/min and ultrafiltration according to the needs of the patient. At the start of the dialysis session, the normal amount of anticoagulation is administered. |
| Reduced anticoagulation dosing | Experimental | Other: anticoagulation dosingPatients are dialyzed during three consecutive hemodialysis sessions with an FX800 Cordiax dialyzer, blood flow of 300mL/min, dialysate flow of 500mL/min and ultrafiltration according to the needs of the patient. At the start of the dialysis session, only one quarter of the normal amount of anticoagulation is administered. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- stable chronic hemodialysis patient
- well functioning vascular access
Key exclusion criteria (5 listed)
- ultrafiltration rate higher than 4 litre per session
- use of antiplatelets or anticoagulants (apart from acetylsalicylic acid)
- known coagulation disorder
- active inflammation
- malignancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| anticoagulation dosingIn one arm the normal amount of anticoagulation is administered at the dialysis start, while this is only a quarter of the normal amount of anticoagulation in the other arm. | Other | Normal anticoagulation dosing, Reduced anticoagulation dosing |
Primary outcome
Intrapatient variability of dialyzer fiber patency
Time frame: 2 months
The intrapatient variability of the dialyzer fiber patency (i.e. percentage open fibers post dialysis) and the intraclass correlation coefficient (ICC) of fiber patency are calculated from the results of the post dialysis micro CT images of the dialyzer, as scanned after three consecutive dialysis sessions with the same anticoagulation dosing: one week with full anticoagulation and one week with reduced (1/4) anticoagulation. Outcome = intrapatient variability of the percentage open fibers. Tool = micro CT scanning and computer-based determination of fiber patency.
3 secondary outcomes
Impact of dialyzer storage and transport on micro CT images of dialyzer fibers
Time frame: 3 months
Association between whole blood thrombin generation test and fiber patency
Time frame: 2 months
Difference in fiber patency using normal versus reduced anticoagulation dosing.
Time frame: 2 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Feb 2024.
- Individual participant dataSharing planned: No
Related trials for Hemodialysis Complication
Active, not recruitingPhase 1/2
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
Staphylococcus Aureus
Not yet recruiting
Effects of Horticultural Therapy on Acute Stress and Salivary Cortisol Levels in Hemodialysis Patients
End-Stage Renal Disease, Renal Dialysis
Not yet recruiting
Manual Acupuncture for Intradialytic Nausea and Vomiting in Patients Undergoing Hemodialysis
Intradialytic Nausea and Vomiting, Chronic Kidney Disease
Recruiting
Laser Acupuncture for Fatigue in Hemodialysis Patients
ESRD (End Stage Renal Disease), Dialysis
RecruitingPhase 2
Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus
Pruritus, Chronic Kidney Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Wim Van Biesen, PhD principal investigator
University Hospital, Ghent
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing anticoagulation dosing in people with Hemodialysis Complication and Anticoagulants, run by University Hospital, Ghent at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Intrapatient variability of dialyzer fiber patency (time frame: 2 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Feb 2024.